Fig. 7: Intravenous administration of MSCs mitigates vascular dysfunction in diabetic mice. | Cell Death & Disease

Fig. 7: Intravenous administration of MSCs mitigates vascular dysfunction in diabetic mice.

From: MSCs ameliorates hyperglycemia-induced endothelial injury through modulation of mitochondrial dynamics

Fig. 7: Intravenous administration of MSCs mitigates vascular dysfunction in diabetic mice.The alternative text for this image may have been generated using AI.

A, B Aortas were isolated and prepared en face from db/m and db/db mice and stained for MitoSOX, fluorescence was calculated as mean fluorescence intensity (MFI) (n = 6 mice/group). Data are shown as means ± SD. *P < 0.05. C, D DAF-FM staining was performed to assess NO, quantification of NO levels was based on measurement of MFI (n = 6 mice/group). Data are shown as means ± SD. *P < 0.05. E, F Acetylcholine (Ach)-induced endothelium-dependent and sodium nitroprusside (SNP)-induced endothelium-independent vasorelaxation in db/m and db/db mice aorta precontracted with phenylephrine (n = 6 mice/group). Data are shown as means ± SD. (*P < 0.05 vs. db/m, &P < 0.05 vs. db/db, #P < 0.05 vs. db/db + MSCs). G–I Representative images of immunohistochemical staining and quantification of positive staining for ICAM1 and VCAM1 staining in sections of aorta from different groups (n = 6 mice/group). Data are shown as means ± SD. *P < 0.05. Data were analyzed using one-way ANOVA with Tukey’s post hoc test.

Back to article page